$IKT

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. On July 29, 2026, we entered into an exchange agreement with RA Capital Healthcare Fund, L.P., or RA Capital, pursuant to which RA Capital exchanged 18,030,000 shares of our common stock, par value $0.001 per share, or common st

Biotech stocks hit 52-week highs on July 24, 2026, including Inhibikase Therapeutics (IKT) at $2.53 after FDA orphan drug designation for IKT-001 and Phase 3 IMPROVE-PAH progress. Jazz Pharmaceuticals (JAZZ) reached $256.75, with Q1 2026 revenue up 19% to $1.1B. Halozyme (HALO) hit $82.99, Q1 revenue $376M (+42%). Corcept (CORT) rose to $97.63, Q1 revenue $164M. Liquidia (LQDA) reached $91.10 on YUTREPIA revenue and net income.

Inhibikase Therapeutics (IKT) said it sold 25 million shares via an at-the-market facility to RA Capital Management, raising $50 million in gross proceeds. The company plans to use the funds, plus reserves, to support operations through topline data from Part B of its Phase 3 IMPROVE-PAH study for IKT-001, pending warrant exercise. Shares rose about 5% to $2.06.

Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven

Inhibikase Therapeutics (Nasdaq: IKT) said it granted non-qualified stock options to seven newly hired non-executive employees under its 2026 Inducement Equity Plan. Up to 981,243 shares were covered; options priced at $2.03 per share (June 30, 2026 close) with a 10-year term and vesting starting after one year.

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001750149 --12-31 0001750149 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J

Inhibikase Therapeutics reported its first-quarter 2026 financial results, showing a net loss of $16.4 million but maintaining a strong cash position of $170.4 million. The company announced significant progress for its IKT-001 drug in pulmonary arterial hypertension (PAH), including the enrollment of the first patient in the global Phase 3 IMPROVE-PAH trial, which has regulatory approvals in 16 countries. Inhibikase also submitted an Orphan Drug Designation application for IKT-001 to the U.S. FDA, highlighting advancements in its clinical development.

Inhibikase Therapeutics Inc has reported its earnings summary for the quarter ended December 31. The report is a brief overview of the company's financial results for that period.

Inhibikase Therapeutics (NASDAQ:IKT) saw a significant increase in short interest during December, rising by 29.0% to 5,345,574 shares as of December 15th. This represents about 7.7% of the company's stock, resulting in a days-to-cover ratio of 13.8 days based on average daily volume. Analyst ratings are mixed but lean positive, with a MarketBeat consensus of "Buy," including recent upgrades to "Strong Buy" from Cantor Fitzgerald and Lifesci Capital.